Xianying Pan

Statistics

Publications

Citations

1.2K

H-Index

Active since

2014

Affiliations

Bristol-Myers Squibb (United States)(Current)

Pfizer (United States)

Aalborg University

STATinMED (United States)

Ochsner Medical Center

Xianying Pan is an author at Bristol-Myers Squibb (United States) specializing in clinical pharmacology, anticoagulant therapy, and cardiovascular pharmacotherapy.

Publications per year

2014–2020

Publications

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients

Gregory Y.H. Lip, Allison Keshishian, Xiaoyan Li et al. · Stroke · 2018 · 318 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Allison Keshishian, Shital Kamble, Xianying Pan et al. · Thrombosis and Haemostasis · 2016 · 261 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

Xiaoyan Li, Steve Deitelzweig, Allison Keshishian et al. · Thrombosis and Haemostasis · 2017 · 161 citations · Full text

Medicine, Cardiology, Pharmacology +15

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States

Gregory Y.H. Lip, Xianying Pan, Shital Kamble et al. · International Journal of Clinical Practice · 2016 · 105 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Gregory Y.H. Lip, Xianying Pan, Shital Kamble et al. · PLoS ONE · 2018 · 56 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 15